News
ALVR
--
0.00%
--
AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020.
Business Wire · 2d ago
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition taking place virtually December 5 – 8, 2020. Details of the presentations at ASH are as follows:Presentation Title: Using Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells to Treat High Risk Patients with COVID-19* Session Name: Adoptive Immunotherapy: Mechanisms and New Approaches: Adoptive Cell Therapy beyond CAR T cells Session Date & Time: Monday, December 7, 2020, 9 – 10:30 a.m. Presentation Time: 10:00 a.m. PT (1:00 p.m. ET) Presenter: Spyridoula Vasileiou, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital Abstract Number: 612*This abstract will be highlighted in an ASH press briefing on Saturday, December 5, 8:00 a.m. PT (11:00 – 11:30 a.m. ET.)Presentation Title: Treatment of severe, drug-refractory viral infections with allogeneic, off-the-shelf multi-virus specific T cell therapy in patients following HSCT: Results from a phase 2 Study Session Name: Adoptive Immunotherapy: Mechanisms and New Approaches: Adoptive Cell Therapy beyond CAR T cells Session Date & Time: Monday, December 7, 2020, 9 – 10:30 a.m. Presentation Time: 9:15 a.m. PT (12:15 p.m. ET) Presenter: Ifigeneia Tzannou, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital Abstract Number: 609Presentation Title: Economic and Clinical Burden of Virus Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Session Name: Health Services Research—Malignant Conditions (Lymphoid Disease) I Session Date and Time: Monday, December 7, 2020, 1:30 – 3:00 p.m. Presentation Time: 2:45 p.m. PT (5:45 p.m. ET) Presenter: Joseph P. McGuirk, DO, The University of Kansas Cancer Center Abstract Number: 747About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding AlloVir’s development and regulatory status of our product candidates and its strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to AlloVir’s financial results, the timing for completion of AlloVir’s clinical trials of its product candidates, whether and when, if at all, AlloVir’s product candidates will receive approval from the U.S. Food and Drug Administration, or FDA, or other foreign regulatory authorities, competition from other biopharmaceutical companies, and other risks identified in AlloVir’s SEC filings. AlloVir cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. AlloVir disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent AlloVir’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.Media contact: Courtney Heath ScientPR ‍AlloVirPR@scientpr.com   617-872-2462                Investor contact: Medha Chadha AlloVir ir@allovir.com
GlobeNewswire · 11/04 18:33
AlloVir Gains 14% On FDA Trial Nod For Covid-19 Therapy
Shares of AlloVir jumped 13.6% on Friday after the US Food and Drug Administration (FDA) granted clinical trial approval for its ALVR109, an allogeneic, off-the-shelf virus-specific T cell Covid-19 therapy against SARS-CoV-2. The therapy is being designed and developed to halt the progression of COVID
SmarterAnalyst · 09/21 10:14
AlloVir gets green signal to initiate clinical trial for ALVR109 in COVID-19
The FDA has signed off AlloVir's ([[ALVR]] +6.0%) Investigational New Drug application ((IND)) for ALVR109, an allogeneic, off-the-shelf virus-specific T cell therapy candidate against SARS-CoV-2.In March, the company expanded its research collaboration
Seekingalpha · 09/17 14:38
AlloVir Announces FDA Clearance of Investigational New Drug Application For ALVR109 For Treatment Of High-Risk Coronavirus Patients; Proof-Of-Concept Clinical Trial To Begin Q4 2020
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients - ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy
Benzinga · 09/17 14:06
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept TrialsCAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced the appointment of Ercem Atillasoy, M.D., as the
GlobeNewswire · 09/08 21:15
AlloVir EPS misses by $4.12
AlloVir (ALVR): Q2 GAAP EPS of -$4.43 misses by $4.12.Cash, cash equivalents, and marketable securities of $104.5M.Press Release
Seekingalpha · 09/02 11:42
JP Morgan Initiates Coverage On AlloVir with Overweight Rating, Announces Price Target of $50
JP Morgan analyst Anupam Rama initiates coverage on AlloVir (NASDAQ:ALVR) with a Overweight rating and announces Price Target of $50.
Benzinga · 08/24 15:55
Morgan Stanley Initiates Coverage On AlloVir with Overweight Rating, Announces Price Target of $49
Morgan Stanley analyst Matthew Harrison initiates coverage on AlloVir (NASDAQ:ALVR) with a Overweight rating and announces Price Target of $49.
Benzinga · 08/24 11:36
AlloVir initiated at overweight with $50 price target at JP Morgan
ALVR | Complete AlloVir Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 08/24 11:31
U.S. IPO Weekly Recap: Vital Farms Pops 59% In A 7 IPO Week
Seeking Alpha · 08/01 12:08
AlloVir opens at 18% premium in U.S. debut
Seeking Alpha · 07/30 16:14
AlloVir Shares Open For Trade At $20; IPO Priced At $17/Share
Benzinga · 07/30 15:03
AlloVir Shares Expected To Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade At 10:20 a.m. EDT; IPO Priced At $17/Share
Benzinga · 07/30 13:43
AlloVir prices upsized IPO at $17, to be valued at over $1 billion
AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share. The company sold 16.25 million shares to raise $276.25 million, up from previous expectations to sell 14.75 m
MarketWatch · 07/30 12:53
AlloVir Announces Pricing Of Upsized Initial Public Offering Of 16.25M At $17/Share
Benzinga · 07/30 11:52
AlloVir Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of 16,250,000 shares of common stock at a public offering price of
GlobeNewswire · 07/30 11:32
IPO market braces for another 7 deals this week and yet another blank-check company
marketwatch.com · 07/29 06:10
IPO Update: AlloVir Proposes Terms For $251 Million IPO
Seeking Alpha · 07/26 16:18
AlloVir sets IPO terms
AlloVir (ALVR) has filed an updated preliminary prospectus for an IPO of 14.75M common shares at $16-18 per share. AlloVir on deck for IPO
seekingalpha · 07/23 15:44
Webull provides a variety of real-time ALVR stock news. You can receive the latest news about Allovir, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALVR
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
More